Meeting
2021 Genitourinary Cancers Symposium
Treatment decisions and outcomes for NCCN favorable intermediate-risk prostate cancer patients after receiving the 17-gene genomic prostate cancer score result.
Authors
Eric Margolis
Urologic Research and Consulting, Englewood, NJ
Eric Margolis , John Bennett , Marina Pavlova , Kenny Wong , Christopher Michael Pieczonka , Benjamin H. Lowentritt , Edward M. Uchio , Melissa Conrad Stoppler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Localized Disease
Track
Prostate Cancer - Localized
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 218)
DOI
10.1200/JCO.2021.39.6_suppl.218
Abstract #
218
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
The impact of genomic biomarkers on a validated clinical risk prediction model for upgrading/upstaging among men with low-risk prostate cancer.
First Author: Avery Braun
Poster
2014 Genitourinary Cancers Symposium
Evaluation of the Oncotype DX genomic prostate score for risk stratification in prostate cancer patients considered candidiates for active surveilance.
First Author: Ganesh K Kartha
Poster
2022 ASCO Genitourinary Cancers Symposium
Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.
First Author: Daniel Eidelberg Spratt
Poster
2018 Genitourinary Cancers Symposium
A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.
First Author: Melvin Chua